Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Phase II evaluation of zanubrutinib plus R-CHOP for untreated diffuse large B-cell lymphoma with a specific gene alteration

  • By

  • Qunling Zhang

  • Shiyu Jiang

  • Ran Wei

  • Wenhao Zhang

  • Longlong Bao

  • Yizhen Liu

  • Jia Jin

  • Fangfang Lv

  • Chuanxu Liu

  • Xiaojian Liu

  • Hui Sun

  • Jiachen Wang

  • Rong Tao

  • Xiaoyan Zhou

  • Junning Cao

  • November 5, 2026

Share

  • 1

    A correction to the Blood Cancer Journal article was published online on July 1, 2026.

  • 2

    The article concerns phase II evaluation of zanubrutinib plus R-CHOP for untreated diffuse large B-cell lymphoma with a specific gene alteration.

  • 3

    The correction states that the updated version of Figure 2 was not included in the article.

  • 4

    The original article has undergone correction.

  • 5

    The correction has DOI 10.1038/s41408-026-01553-4.

Original Source(s)

Related Content